XOMA Royalty’s Pulmokine brings seralutinib to pipeline

3 December 2024

California’s XOMA Royalty Corporation (Nasdaq: XOMA) has announced that it now owns an economic interest in seralutinib, a Phase III asset being studied in pulmonary arterial hypertension (PAH), through its $20 million acquisition of Pulmokine, a privately-held company.

In 2017, Pulmokine licensed seralutinib to Gossamer Bio (Nasdaq: GOSS) and, in 2024, the latter firm signed a global collaboration and license agreement with Italy’s Chiesi Farmaceutici. A Phase III study for PAH is ongoing and is expected to read out in the fourth quarter of 2025.

XOMA Royalty is a biotech royalty aggregator that acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotech companies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK